Why the study?
Do specific genetic polymorphisms and serum biomarkers (NT-proBNP, soluble Fas-L) predict the development of anthracycline-induced cardiotoxicity in women without pre-existing cardiovascular disease?
Do specific genetic polymorphisms and serum biomarkers (NT-proBNP, soluble Fas-L) predict the development of anthracycline-induced cardiotoxicity in women without pre-existing cardiovascular disease?
Answers are grounded in this paper and cite their sources.
Specific genetic polymorphisms and serum biomarkers may serve as non-invasive predictors for the development of anthracycline-induced cardiotoxicity in women without prior cardiovascular disease.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Kopeva et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: